Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
107 hedge funds and large institutions have $167M invested in Paratek Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 40 reducing their positions, and 10 closing their positions.
13% more capital invested
Capital invested by funds: $148M → $167M (+$19.1M)
1% less funds holding
Funds holding: 108 → 107 (-1)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
38% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 40
47% less call options, than puts
Call options by funds: $776K | Put options by funds: $1.47M
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.03M |
| 2 |
BC
Bruce & Co
Chicago,
Illinois
|
+$1.69M |
| 3 |
Two Sigma Advisers
New York
|
+$1.09M |
| 4 |
Morgan Stanley
New York
|
+$918K |
| 5 |
CM
CM Management
Gulf Breeze,
Florida
|
+$828K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$1.29M |
| 2 |
Renaissance Technologies
New York
|
-$1.13M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$1.06M |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$879K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$733K |
PRTK Hedge Fund Activity: Q1 2021 in Review
107 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q1 2021, worth a combined $167M — up 13% from $148M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PRTK and 9 opened new positions — a net loss of 1 holder — while 40 trimmed existing stakes and 25 added.
The largest buyer was Granahan Investment Management, adding an estimated $2.03M. The largest seller was D.E. Shaw & Co, cutting an estimated $1.29M.
- 107 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q1 2021, down from 108 in Q4 2020.
- Funds reported $167M of Paratek Pharmaceuticals, Inc. stock for Q1 2021, up 13% quarter-over-quarter.
- 9 funds opened new Paratek Pharmaceuticals, Inc. positions in Q1 2021 and 10 closed out, a net change of -1 holder.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q1 2021 was Granahan Investment Management, an estimated $2.03M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q1 2021 was D.E. Shaw & Co, an estimated $1.29M sold.
Based on aggregated 13F filings for Q1 2021.